223 related articles for article (PubMed ID: 27765293)
1. Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study.
Azman AS; Parker LA; Rumunu J; Tadesse F; Grandesso F; Deng LL; Lino RL; Bior BK; Lasuba M; Page AL; Ontweka L; Llosa AE; Cohuet S; Pezzoli L; Sodjinou DV; Abubakar A; Debes AK; Mpairwe AM; Wamala JF; Jamet C; Lessler J; Sack DA; Quilici ML; Ciglenecki I; Luquero FJ
Lancet Glob Health; 2016 Nov; 4(11):e856-e863. PubMed ID: 27765293
[TBL] [Abstract][Full Text] [Related]
2. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial.
Bhattacharya SK; Sur D; Ali M; Kanungo S; You YA; Manna B; Sah B; Niyogi SK; Park JK; Sarkar B; Puri MK; Kim DR; Deen JL; Holmgren J; Carbis R; Dhingra MS; Donner A; Nair GB; Lopez AL; Wierzba TF; Clemens JD
Lancet Infect Dis; 2013 Dec; 13(12):1050-6. PubMed ID: 24140390
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
Raghava Mohan V; Raj S; Dhingra MS; Aloysia D'Cor N; Singh AP; Saluja T; Kim DR; Midde VJ; Kim Y; Vemula S; Narla SK; Sah B; Ali M
PLoS One; 2019; 14(6):e0218033. PubMed ID: 31211792
[TBL] [Abstract][Full Text] [Related]
4. Use of a cholera rapid diagnostic test during a mass vaccination campaign in response to an epidemic in Guinea, 2012.
Martinez-Pino I; Luquero FJ; Sakoba K; Sylla S; Haile M; Grais RF; Ciglenecki I; Quilici ML; Page AL
PLoS Negl Trop Dis; 2013; 7(8):e2366. PubMed ID: 23967359
[TBL] [Abstract][Full Text] [Related]
5. Use of Vibrio cholerae vaccine in an outbreak in Guinea.
Luquero FJ; Grout L; Ciglenecki I; Sakoba K; Traore B; Heile M; Diallo AA; Itama C; Page AL; Quilici ML; Mengel MA; Eiros JM; Serafini M; Legros D; Grais RF
N Engl J Med; 2014 May; 370(22):2111-20. PubMed ID: 24869721
[TBL] [Abstract][Full Text] [Related]
6. First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea, 2012.
Luquero FJ; Grout L; Ciglenecki I; Sakoba K; Traore B; Heile M; Dialo AA; Itama C; Serafini M; Legros D; Grais RF
PLoS Negl Trop Dis; 2013; 7(10):e2465. PubMed ID: 24147164
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of an oral cholera vaccine campaign to prevent clinically-significant cholera in Odisha State, India.
Wierzba TF; Kar SK; Mogasale VV; Kerketta AS; You YA; Baral P; Khuntia HK; Ali M; Kim YH; Rath SB; Bhattachan A; Sah B
Vaccine; 2015 May; 33(21):2463-9. PubMed ID: 25850019
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of one dose of killed oral cholera vaccine in an endemic community in the Democratic Republic of the Congo: a matched case-control study.
Malembaka EB; Bugeme PM; Hutchins C; Xu H; Hulse JD; Demby MN; Gallandat K; Saidi JM; Rumedeka BB; Itongwa M; Tshiwedi-Tsilabia E; Kitoga F; Bodisa-Matamu T; Kavunga-Membo H; Bengehya J; Kulondwa JC; Debes AK; Taty N; Lee EC; Lunguya O; Lessler J; Leung DT; Cumming O; Okitayemba PW; Mukadi-Bamuleka D; Knee J; Azman AS
Lancet Infect Dis; 2024 May; 24(5):514-522. PubMed ID: 38246191
[TBL] [Abstract][Full Text] [Related]
9. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam.
Trach DD; Clemens JD; Ke NT; Thuy HT; Son ND; Canh DG; Hang PV; Rao MR
Lancet; 1997 Jan; 349(9047):231-5. PubMed ID: 9014909
[TBL] [Abstract][Full Text] [Related]
10. Long-term effectiveness of one and two doses of a killed, bivalent, whole-cell oral cholera vaccine in Haiti: an extended case-control study.
Franke MF; Ternier R; Jerome JG; Matias WR; Harris JB; Ivers LC
Lancet Glob Health; 2018 Sep; 6(9):e1028-e1035. PubMed ID: 30103980
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study.
Khatib AM; Ali M; von Seidlein L; Kim DR; Hashim R; Reyburn R; Ley B; Thriemer K; Enwere G; Hutubessy R; Aguado MT; Kieny MP; Lopez AL; Wierzba TF; Ali SM; Saleh AA; Mukhopadhyay AK; Clemens J; Jiddawi MS; Deen J
Lancet Infect Dis; 2012 Nov; 12(11):837-44. PubMed ID: 22954655
[TBL] [Abstract][Full Text] [Related]
12. Neighborhood-targeted and case-triggered use of a single dose of oral cholera vaccine in an urban setting: Feasibility and vaccine coverage.
Parker LA; Rumunu J; Jamet C; Kenyi Y; Lino RL; Wamala JF; Mpairwe AM; Muller V; Llosa AE; Uzzeni F; Luquero FJ; Ciglenecki I; Azman AS
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005652. PubMed ID: 28594891
[TBL] [Abstract][Full Text] [Related]
13. Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model.
Kar SK; Sah B; Patnaik B; Kim YH; Kerketta AS; Shin S; Rath SB; Ali M; Mogasale V; Khuntia HK; Bhattachan A; You YA; Puri MK; Lopez AL; Maskery B; Nair GB; Clemens JD; Wierzba TF
PLoS Negl Trop Dis; 2014 Feb; 8(2):e2629. PubMed ID: 24516675
[TBL] [Abstract][Full Text] [Related]
14. Progress and Challenges in Using Oral Cholera Vaccines to Control Outbreaks: The Médecins Sans Frontières Experience.
Ciglenecki I; Azman AS; Jamet C; Serafini M; Luquero FJ; Cabrol JC
J Infect Dis; 2018 Oct; 218(suppl_3):S165-S166. PubMed ID: 30239901
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti.
Charles RC; Hilaire IJ; Mayo-Smith LM; Teng JE; Jerome JG; Franke MF; Saha A; Yu Y; Kováč P; Calderwood SB; Ryan ET; LaRocque RC; Almazor CP; Qadri F; Ivers LC; Harris JB
PLoS Negl Trop Dis; 2014 May; 8(5):e2828. PubMed ID: 24786645
[TBL] [Abstract][Full Text] [Related]
16. Epidemiological description of a protracted cholera outbreak in Tonj East and Tonj North counties, former Warrap State, South Sudan, May-Oct 2017.
Nsubuga F; Garang SC; Tut M; Oguttu D; Lubajo R; Lodiongo D; Lasuba M; Mpairwe A
BMC Infect Dis; 2019 Jan; 19(1):4. PubMed ID: 30606126
[TBL] [Abstract][Full Text] [Related]
17. Immune Responses to an Oral Cholera Vaccine in Internally Displaced Persons in South Sudan.
Iyer AS; Bouhenia M; Rumunu J; Abubakar A; Gruninger RJ; Pita J; Lino RL; Deng LL; Wamala JF; Ryan ET; Martin S; Legros D; Lessler J; Sack DA; Luquero FJ; Leung DT; Azman AS
Sci Rep; 2016 Oct; 6():35742. PubMed ID: 27775046
[TBL] [Abstract][Full Text] [Related]
18. Safety of a killed oral cholera vaccine (Shanchol) in pregnant women in Malawi: an observational cohort study.
Ali M; Nelson A; Luquero FJ; Azman AS; Debes AK; M'bang'ombe MM; Seyama L; Kachale E; Zuze K; Malichi D; Zulu F; Msyamboza KP; Kabuluzi S; Sack DA
Lancet Infect Dis; 2017 May; 17(5):538-544. PubMed ID: 28161570
[TBL] [Abstract][Full Text] [Related]
19. Implementation research: reactive mass vaccination with single-dose oral cholera vaccine, Zambia.
Poncin M; Zulu G; Voute C; Ferreras E; Muleya CM; Malama K; Pezzoli L; Mufunda J; Robert H; Uzzeni F; Luquero FJ; Chizema E; Ciglenecki I
Bull World Health Organ; 2018 Feb; 96(2):86-93. PubMed ID: 29403111
[TBL] [Abstract][Full Text] [Related]
20. Alternative observational designs to estimate the effectiveness of one dose of oral cholera vaccine in Lusaka, Zambia.
Ferreras E; Blake A; Chewe O; Mwaba J; Zulu G; Poncin M; Rakesh A; Page AL; Quilici ML; Azman AS; Cohuet S; Ciglenecki I; Malama K; Chizema-Kawesha E; Luquero FJ
Epidemiol Infect; 2020 Mar; 148():e78. PubMed ID: 32167038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
